Digital gangrene is a rare presenting feature of childhood lupus and only a reported incidence of 1.3%. We describe two cases of pediatric onset systemic lupus erythematosus (SLE), both 16 years old, presenting with digital gangrene and the successful salvage of the digits after using intravenous cyclophosphamide for immunosuppression and use of intravenous prostaglandin E1 infusions for limb reperfusion. Both of the patients responded exceptionally to the infusions with resolution of gangrene and near-total preservation of the functionality of toes.
DuboisELArterberryJD. Gangrene as a manifestation of systemic lupus erythematosus. JAMA, J Am Med Assoc1962; 181(5): 366–374.
2.
KamphuisSSilvermanED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol2010; 6(9): 538–546.
3.
DesclouxEDurieuICochatP, et al.Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. Rheumatology2009; 48(7): 779–784.
4.
AlghamdiMA. Digital gangrene as the initial presentation of systemic lupus erythematosus without secondary antiphospholipid syndrome: case report. Z.U.M.J2015; 21(3). Available from:https://zumj.journals.ekb.eg/article_4519.html
5.
HauptmanHWRuddySRobertsWN. Reversal of the vasospastic component of lupus vasculopathy by infusion of prostaglandin E1. J Rheumatol1991; 18(11): 1747–1752.
6.
YoshikawaYMizutaniHShimizuM. Systemic lupus erythematosus with ischemic peripheral neuropathy and lupus anticoagulant: response to intravenous prostaglandin E1. Cutis1996; 58(6): 393–396.
7.
García HernándezFJOcaña MedinaCMateos RomeroL, et al.Iloprost en el fenómeno de Raynaud grave y las úlceras isquémicas de las enfermedades sistémicas [Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases]. Med Clin2004; 122(13): 501–504.
8.
CruzJEWardAAnthonyS, et al.Evidence for the use of epoprostenol to treat raynaud's phenomenon with or without digital ulcers. Ann Pharmacother2016; 50(12): 1060–1067. DOI: 10.1177/1060028016660324
9.
Machado-AlbaJEMachado-DuqueME. Use of intravenous alprostadil in patients with severe critical ischemia of the lower limbs. Vascular2019; 27(3): 318–323. DOI: 10.1177/1708538118816267
10.
KurienJSSanshoEUVargheseS, et al.A study on prostaglandin E1 therapy in critical limb ischaemia patients to evaluate the improvement in vascularity. International Surgery Journal2017; 4: 3306–3310.
11.
ZiaeeVYeganehMHMoradinejadMH. Peripheral gangrene: a rare presentation of systemic lupus erythematosus in a child. The American journal of case reports. 2013; 14: 337–340.
12.
AlzughayyarTZZalloumJSElqadiMN, et al.Systemic lupus erythematosus with multiple autoimmune disease presented with extensive peripheral gangrene. Case Reports in Rheumatology2020; 2020: 8278275.
13.
NagarRPGuptaAKNagarT. Juvenile SLE presenting as digital gangrene - a case report. Int J Health Sci Res2015; 5(11):400–402
14.
ShettyVBRaoSKrishnamurthyPN, et al.Peripheral gangrene during infancy: a rare presentation of systemic lupus erythematosus. Arch Dis Child2001; 85(4): 335–336.
15.
AlalawiZMAlkenanySAlmahroosF, et al.Peripheral gangrene as the initial presentation of systemic lupus erythematosus in emergency department. Cureus2020; 12(1): e6667.
16.
SonkarSKKumarSAtamV, et al.Digital dry gangrene as a primary manifestation of systemic lupus erythematosus. BMJ Case Rep2019; 12(12): e230869.
17.
VocksEWelckerMRingJ. Digital gangrene: a rare skin symptom in systemic lupus erythematosus. J Eur Acad Dermatol Venereol2000; 14(5): 419–421.
18.
HarmonSMOltmannsKLMinKW. Large vessel occlusion with vasculitis in systemic lupus erythematosus. South Med J1991; 84(9): 1150–1154.
19.
AdelowoOOlaosebikanHAjaniW, et al.Digital gangrene as the initial presentation of systemic lupus erythematosus. Case Reports2012; 2012: bcr2012006259.
20.
LiuAZhangWTianX, et al.Prevalence, risk factors and outcome of digital gangrene in 2684 lupus patients. Lupus. 2009; 18(12): 1112–1118.
21.
NkeckJREndombaFTANdoadoumgueAL, et al.Gangrene of all digits and toes attributable to systemic lupus erythematosus with negative antiphospholipid antibodies. J Clin Rheumatol2019; 25(6): e79–e80.
22.
MarasiniBMassarottiMBottassoB, et al.Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon. Scand J Rheumatol2004; 33(4): 253–257.
